Allogene Therapeutics ALLO Lease Liability Payments - Due Year Two
Lease Liability Payments - Due Year Two at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's lease liability payments - due year two.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's lease liability payments - due year two?
- Allogene Therapeutics (ALLO) reported lease liability payments - due year two of $14.04M in Q1 2026.
- How has Allogene Therapeutics's lease liability payments - due year two changed year-over-year?
- Allogene Therapeutics's lease liability payments - due year two increased by 3.1% year-over-year, from $13.61M to $14.04M.
- What does lease liability payments - due year two mean?
- This metric identifies the total cash payments required for operating and finance leases in the second year following the current balance sheet date. It helps investors forecast long-term fixed cost commitments and cash flow requirements. It is essential for modeling the company's future solvency and operational leverage.